earthbound

Historic mission from Houston space tech company plans for splashdown

Ax-1 is headed back to Earth after 12 days of research on the ISS.

Photo courtesy of SpaceX

After spending 12 days in space, a historic commercial space mission will splash back down on Earth this week.

Houston-based Axiom Space’s first mission Axiom mission 1 (Ax-1), which took off April 8 and connected to the International Space Station, has announced its plans for undocking and splashdown.

After some initial bad weather postponed the process, the four-member private astronaut crew now is aiming to undock at about 9 pm tonight, April 19, and then land off the coast of Florida at around 2:24 pm tomorrow, April 20. Just like launch, the coverage of both events will be available at Axiom's website.

The mission on SpaceX’s spacecraft sent four multinational private astronauts — Commander Michael López-Alegría, Pilot Larry Connor, Mission Specialist Eytan Stibbe, and Mission Specialist Mark Pathy — to the ISS to conduct research and familiarize Axiom with launch, docking, and more.

Axiom Space, which reached $1 billion valuation and joined the Houston unicorn club last year after a $130 million investment round, is working on the first commercial space station to replace the ISS. The first launch of that mission is expected in late 2024. In the meantime, Axiom has a series of commercial launches to the existing station currently in orbit in order to prepare for development and orchestration of Axiom Station.

The Ax-1 mission, which has provided daily updates, has conducted over 20 research projects and even hit a few milestones, including:

The first-ever music duet performance in space — Commander López-Alegría and Neo-Classical Piano Prodigy BLKBOK made music and space history with their piano and keyboard duet
The Aging and Heart Health investigation, an experiment from the Mayo Clinic — a study that analyzes human cells for genetic markers of cellular aging and explores cardiac-like cells' adaptation to microgravity
Observation of Transient Luminous Events — Specialist Stibbe completed a space observation experiment and photographed a lightning storm over Darwin, Australia, to enhance understanding of the electrical processes in the atmosphere and to determine whether there’s a connection with climate change
Testing of the Holoportation system — Mission Specialist Pathy set up two-way AI technology that will allow the ability of future crew members to explore deep space with the ability to virtually bring friends, family, and physicians close with them so that they can get an on-Earth experience
Several outreach calls to Earth to STEM students from around the world — this included a call to children at Space Center Houston

Axiom shares more details on its mission research projects — which span technologies such as future space habitats, cancer research, and devices to purify air on space stations — online.

“As the first step on a path to building a diverse, thriving economy in low-Earth orbit, Axiom has partnered with leaders in academia and industry to bring new users and new investigations in research to the space station,” says Christian Maender, director of In-space Manufacturing and Research for Axiom Space, in a news release. “The collection of biological and technological tests during the Ax-1 mission represent a breadth of research that will inform everything from human health considerations to novel infrastructure and design for our future homes away from Earth, beginning with Axiom Station.”

---

This article originally appeared on our sister site InnovationMap.

science technology

medical innovation

Houston development opens new factory for next generation organ transplants

Courtesy of McCord

The new factory is the latest addition to Generation Park.

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

---

This story was originally published on our sister site, InnovationMap.

medicine innovation